DexCom, Inc. (DXCM): A Bull Case Theory
We came across a bullish thesis on DexCom, Inc. (DXCM) on Substack by Na’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.
Dexcom Inc (DXCM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 12,924,000 | $11,585,037 | -30% | 0.1% | |
| 2. | 5,000,000 | $4,464,800 | 0.23% | ||
| 3. | Bailard Inc Thomas Bailard | 57,707 | $3,940,811 | -2% | 0.1% |
| 4. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 45,841 | $3,130,482 | -24% | 1.38% |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 20,862 | $1,424,667 | -38% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.01 | 25,000 | Director | 58,502 | 2017-11-07 | Filing | |
| $49.61 | 10,000 | Director | 33,502 | 2017-11-06 | Filing | |
| $15.50 | 70,000 | Director | 121,975 | 2013-03-11 | Filing | |
| $10.37 | 1,000 | Director | 6,000 | 2012-03-08 | Filing | |
| $10.34 | 1,000 | Director | 5,000 | 2012-03-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.33 | 352 | Director | 22,997 | 2025-03-17 | Filing | |
| $70.38 | 14,076 | Officer | 313,497 | 2025-03-12 | Filing | |
| $70.38 | 13,000 | Officer | 105,602 | 2025-03-12 | Filing | |
| $70.38 | 12,001 | Officer | 123,481 | 2025-03-12 | Filing | |
| $70.38 | 11,176 | Officer | 115,805 | 2025-03-12 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 47,455,899 | $3,240,763,341 | 0.06% | |
| 2. | 39,241,177 | $2,679,779,952 | 0.06% | |
| 3. | 14,179,830 | $968,340,590 | 0.85% | |
| 4. | 10,523,246 | $718,632,455 | 0.5% | |
| 5. | 4,476,653 | $305,710,553 | 0.06% |
News See All
11 Best Medical Device Stocks to Buy Now
On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community.
DexCom, Inc. (NASDAQ:DXCM) Q1 2025 Earnings Call Transcript
Operator: Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call.
DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns
Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here.
10 Best Diabetes Stocks To Buy According to Billionaires
The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income countries.
10 Best Growth Stocks Under $100 to Buy Now
Growth stocks are shares of companies which are expected to grow their revenue and earnings at a faster rate than the market average.
12 Best Internet of Things Stocks To Buy According to Analysts
According to the IOT analytics, 2024 was a poor year for the Internet of Things sector, particularly due to the headwinds from the hardware sector.
DexCom, Inc. (NASDAQ:DXCM) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the DexCom, Inc.
10 Best Medical Device Stocks To Buy According to Hedge Funds
According to a report by Mordor Intelligence, the medical devices market has a size of $681.57 billion as of 2025.
Here’s Why Aristotle Atlantic Focus Growth Strategy Sold its Stake in DexCom (DXCM)
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S.
Billionaire Hedge Funds
